The Impact of Comorbidity on Cancer and Its Treatment

被引:506
作者
Sarfati, Diana [1 ]
Koczwara, Bogda [2 ]
Jackson, Christopher [3 ,4 ]
机构
[1] Univ Otago, Canc Control & Screening Res Grp, Wellington, New Zealand
[2] Flinders Univ S Australia, Flinders Ctr Innovat Canc, Adelaide, SA, Australia
[3] Univ Otago, Dunedin Sch Med, Dept Med, Med, Wellington, New Zealand
[4] Southern Dist Hlth Board, Dunedin, New Zealand
关键词
cancer; chronic disease; comorbidity; multimorbidity; neoplasms; COMPREHENSIVE GERIATRIC ASSESSMENT; POTENTIAL-DRUG INTERACTIONS; QUALITY-OF-LIFE; III COLON-CANCER; NON-INDIGENOUS AUSTRALIANS; ADJUVANT CHEMOTHERAPY USE; COLORECTAL-CANCER; OLDER PATIENTS; LUNG-CANCER; ELDERLY-PATIENTS;
D O I
10.3322/caac.21342
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Comorbidity is common among cancer patients and, with an aging population, is becoming more so. Comorbidity potentially affects the development, stage at diagnosis, treatment, and outcomes of people with cancer. Despite the intimate relationship between comorbidity and cancer, there is limited consensus on how to record, interpret, or manage comorbidity in the context of cancer, with the result that patients who have comorbidity are less likely to receive treatment with curative intent. Evidence in this area is lacking because of the frequent exclusion of patients with comorbidity from randomized controlled trials. There is evidence that some patients with comorbidity have potentially curative treatment unnecessarily modified, compromising optimal care. Patients with comorbidity have poorer survival, poorer quality of life, and higher health care costs. Strategies to address these issues include improving the evidence base for patients with comorbidity, further development of clinical tools to assist decision making, improved integration and coordination of care, and skill development for clinicians. (C) 2016 American Cancer Society.
引用
收藏
页码:338 / 350
页数:13
相关论文
共 188 条
[1]   Survival Benefit of Radical Prostatectomy in Patients with Localized Prostate Cancer: Estimations of the Number Needed to Treat According to Tumor and Patient Characteristics [J].
Abdollah, Firas ;
Sun, Maxine ;
Schmitges, Jan ;
Thuret, Rodolphe ;
Bianchi, Marco ;
Shariat, Shahrokh F. ;
Briganti, Alberto ;
Jeldres, Claudio ;
Perrotte, Paul ;
Montorsi, Francesco ;
Karakiewicz, Pierre I. .
JOURNAL OF UROLOGY, 2012, 188 (01) :73-83
[2]   Influence of Medical Comorbidities on the Presentation and Outcomes of Stage I-III None-Small-Cell Lung Cancer [J].
Ahn, Daniel H. ;
Mehta, Nishi ;
Yorio, Jeffrey T. ;
Xie, Yang ;
Yan, Jingsheng ;
Gerber, David E. .
CLINICAL LUNG CANCER, 2013, 14 (06) :644-650
[3]   Race Disparities Between Black and White Women in the Incidence, Treatment, and Prognosis of Endometrial Cancer [J].
Allard, Jay E. ;
Maxwell, G. Larry .
CANCER CONTROL, 2009, 16 (01) :53-56
[4]  
[Anonymous], 2013, DELIVERING HIGH QUAL
[5]  
[Anonymous], 2002, INNOVATIVE CARE CHRO
[6]  
Balducci Lodovico, 2007, Cancer Control, V14, P7
[7]   Drug interactions in oncology [J].
Beijnen, JH ;
Schellens, JHM .
LANCET ONCOLOGY, 2004, 5 (08) :489-496
[8]   Drug-drug interactions in oncology: Why are they important and can they be minimized? [J].
Blower, P ;
de Wit, R ;
Goodin, S ;
Aapro, M .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 55 (02) :117-142
[9]   Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent [J].
Boulos, DL ;
Groome, PA ;
Brundage, MD ;
Siemens, DR ;
Mackillop, WJ ;
Heaton, JPW ;
Schulze, KM ;
Rohland, SL .
CANCER, 2006, 106 (08) :1804-1814
[10]   Prostate Cancer Treatment and Survival Evidence for Men With Prevalent Comorbid Conditions [J].
Bradley, Cathy J. ;
Dahman, Bassam ;
Anscher, Mitchell .
MEDICAL CARE, 2014, 52 (06) :482-489